Earnings History Data for ARS Pharmaceuticals, Inc. (SPRY) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-11-2024 | PM | SPRY | ARS Pharmaceuticals, Inc. | 1,700 | -0.20 | -0.18 | -0.16 | ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M beats by $1.5M [11/13/2024 6:38 AM] |
13.95 | -2.66 (-16.01%) |
16.00 | -0.61 (-3.67%) |
3.76 - 18.51 | 2,922,554 | 1,310,000 | 30,201 | ||
|
||||||||||||||||||
| 06-08-2024 | AH | SPRY | ARS Pharmaceuticals, Inc. | 959.00 | -0.13 | -0.12 | 0.00 | ARS Pharmaceuticals GAAP EPS of -$0.13 misses by $0.02, revenue of $0.5M misses by $0.17M [8/6/2024 5:51 PM] |
9.58 | -0.20 (-2.06%) |
9.78 | 0.0 (0.00%) |
2.55 - 11.90 | 560,803 | 560,000 | 2,558 | ||
| 09-05-2024 | AH | SPRY | ARS Pharmaceuticals, Inc. | 918.00 | -0.11 | -0.11 | 0.00 | ARS Pharmaceuticals GAAP EPS of -$0.11 [5/9/2024 5:31 PM] |
8.74 | -0.06 (-0.68%) |
9.14 | 0.34 (3.86%) |
2.55 - 11.27 | 247,553 | 480,000 | 100 | ||
| 21-03-2024 | AH | SPRY | ARS Pharmaceuticals, Inc. | 812.00 | -0.07 | -0.14 | 0.00 | ARS Pharmaceuticals reports Q4 results [3/21/2024 5:21 PM] |
8.65 | -0.35 (-3.83%) |
8.99 | -0.01 (-0.11%) |
2.55 - 9.65 | 656,920 | 870,000 | 1,756 | ||
| 10-08-2023 | PM | SPRY | ARS Pharmaceuticals, Inc. | 663.42 | -0.18 | -0.17 | -0.55 | ARS Pharmaceuticals GAAP EPS of -$0.18 beats by $0.03 [8/11/2023 9:58 AM] |
6.82 | -0.03 (-0.51%) |
6.85 | 0.0 (0.00%) |
3.99 - 9.65 | 470,610 | 290,000 | 9,767 | ||
| 15-05-2023 | PM | SPRY | ARS Pharmaceuticals, Inc. | 428.00 | -0.16 | -0.17 | 0.00 | ARS Pharmaceuticals GAAP EPS of -$0.16 [5/15/2023 12:13 PM] |
7.79 | -0.25 (-3.11%) |
0.0 | 0.0 (0.00%) |
2.98 - 9.65 | 3,596,489 | 6,340,000 | 0 | ||